AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12092994 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Excel (D17)
Number of subjects: 81
Study 12092994 — intervention group
Group type: COMPARATOR
Intervention: Manual brush with tartar control dentifrice
Number of subjects: 81
Study 12092994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush
Number of subjects: 81
Study 9820263 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based intervention consisting of 11 yoga postures, given twice weekly for 8 weeks
Number of subjects: 42
Study 9820263 — intervention group
Group type: COMPARATOR
Intervention: Wrist splint to supplement current treatment
Number of subjects: 42
Study 8562352 — intervention group
Group type: COMPARATOR
Intervention: Four-drug chemotherapy regimen (ECMV: etoposide, cyclophosphamide, methotrexate, vincristine)
Number of subjects: 310
Study 8562352 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug chemotherapy regimen (EV: etoposide and vincristine)
Number of subjects: 310
Study 8562352 — intervention group
Group type: COMPARATOR
Intervention: Four-drug chemotherapy regimen (ECMV)
Number of subjects: 310
Study 8562352 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug chemotherapy regimen (EV)
Number of subjects: 310
Study 2012514 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release Sinemet (levodopa/carbidopa)
Number of subjects: 10
Study 2012514 — intervention group
Group type: COMPARATOR
Intervention: Standard Sinemet (levodopa/carbidopa)
Number of subjects: 10
Study 6813484 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 52
Study 6813484 — intervention group
Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM)
Number of subjects: 52
Study 6813484 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF) and Gold sodium thiomalate (GSTM)
Number of subjects: 52
Study 30616671 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional adipose tissue grafting (AT-G)
Number of subjects: 38
Study 30616671 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (SP)
Number of subjects: 38
Study 28229508 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week meditation training based on mindfulness-based stress reduction
Number of subjects: 100
Study 28229508 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 25179761 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeR (AAI‐DDD changeover mode)
Number of subjects: 650
Study 25179761 — intervention group
Group type: COMPARATOR
Intervention: DDD (standard mode)
Number of subjects: 650
Study 24637979 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 UI BTX‐A
Number of subjects: 21
Study 24637979 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 UI BTX‐A
Number of subjects: 21
Study 24637979 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study 21157386 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cycle to fatigue at 75% peak power output (FAT)
Number of subjects: 0
Study 21157386 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐minute cycle alternating 1‐minute 60% and 1 minute 90% Wmax (60/90)
Number of subjects: 0
Study 21157386 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐minute cycle alternating 1‐minute 55% and 4‐minute 80% Wmax (55/80)
Number of subjects: 0
Study 21157386 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting 8 sets of 10 repetitions at 10 repetition maximum (RESIST)
Number of subjects: 0
Study 19472557 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing paste containing 8% arginine and calcium carbonate
Number of subjects: 45
Study 19472557 — intervention group
Group type: COMPARATOR
Intervention: Nupro pumice prophylaxis paste
Number of subjects: 45
Study 17550366 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (up to six sessions)
Number of subjects: 897
Study 17550366 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet on healthy lifestyles
Number of subjects: 897
Study 14634808 — intervention group
Group type: EXPERIMENTAL
Intervention: Action effects with target-compatible color effects (e.g., blue word -> left key -> blue patch)
Number of subjects: 0
Study 14634808 — intervention group
Group type: COMPARATOR
Intervention: Control group without action effects
Number of subjects: 0
Study 14634808 — intervention group
Group type: EXPERIMENTAL
Intervention: Group with target-incompatible action effects
Number of subjects: 0
Study 14634808 — intervention group
Group type: EXPERIMENTAL
Intervention: Color words as action effects
Number of subjects: 0
Study 11203779 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐Sited
Number of subjects: 40
Study 11203779 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed‐Shrinkage
Number of subjects: 40
Study 11203779 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin‐Modified Glass‐Ionomer Cement
Number of subjects: 40
Study 11203779 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable Composite
Number of subjects: 40
Study 9972902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood intermittent cardioplegia (CBIC)
Number of subjects: 20
Study 9972902 — intervention group
Group type: COMPARATOR
Intervention: Warm continuous blood cardioplegia (WCBC)
Number of subjects: 20
Study 8527353 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily
Number of subjects: 161
Study 8527353 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg once daily
Number of subjects: 161
Study 8527353 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 161
Study 8527353 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 161
Study 2689045 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg diltiazem
Number of subjects: 8
Study 2689045 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 8
Study 2689045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1233072 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (8 mg) administered twice daily as a sustained release formulation
Number of subjects: 24
Study 1233072 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 mug) administered by aerosol
Number of subjects: 24
Study 31405750 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine rinse (10% solution, 2500 mg daily, 5 times daily during radiotherapy and 2 weeks post-radiotherapy)
Number of subjects: 32
Study 31405750 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine rinse
Number of subjects: 32
Study 31405750 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 32
Study 27655375 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic Cholecystectomy (MLC)
Number of subjects: 115
Study 27655375 — intervention group
Group type: COMPARATOR
Intervention: Conventional Laparoscopic Cholecystectomy (CLC)
Number of subjects: 115
Study 26314451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 44
Study 26314451 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 44
Study 26314451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet application
Number of subjects: 44
Study 23222413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (2.0 g/day)
Number of subjects: 50
Study 23222413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22016912 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave disinfection (once a week for 3 minutes at 650W)
Number of subjects: 40
Study 22016912 — intervention group
Group type: COMPARATOR
Intervention: Brushing with coconut soap and soft toothbrush (control group)
Number of subjects: 40
Study 18449063 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (10 mg/kg twice daily)
Number of subjects: 1650
Study 18449063 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (14:1; amoxicillin 45 mg/kg twice daily)
Number of subjects: 1650
Study 18449063 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 1650
Study 18449063 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 1650
Study 18449063 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin and Amoxicillin/clavulanate
Number of subjects: 1650
Study 17139433 — intervention group
Group type: EXPERIMENTAL
Intervention: Isothermic carbon dioxide at 37 degrees C
Number of subjects: 30
Study 17139433 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic carbon dioxide at 21 degrees C
Number of subjects: 30
Study 14503827 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 94
Study 14503827 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite
Number of subjects: 94
Study 14503827 — intervention group
Group type: COMPARATOR
Intervention: Control (phosphate-buffered saline)
Number of subjects: 94
Study 10866907 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 0.1 mg/kg IV injection
Number of subjects: 60
Study 10866907 — intervention group
Group type: COMPARATOR
Intervention: placebo (normal saline) IV injection
Number of subjects: 60
Study 10866907 — intervention group
Group type: COMPARATOR
Intervention: diphenhydramine 30 mg IV injection
Number of subjects: 60
Study 9358912 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of 25,000 IU vitamin A and 30 mg beta-carotene
Number of subjects: 18500
Study 9358912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18500
Study 8451310 — intervention group
Group type: COMPARATOR
Intervention: 560 ml of CMW
Number of subjects: 18
Study 8451310 — intervention group
Group type: COMPARATOR
Intervention: 560 ml of APM-sweetened soft drink (340 mg APM)
Number of subjects: 18
Study 8451310 — intervention group
Group type: EXPERIMENTAL
Intervention: 280 ml of APM-sweetened mineral water (340 mg APM)
Number of subjects: 18
Study 8451310 — intervention group
Group type: COMPARATOR
Intervention: 280 ml of carbonated mineral water (CMW)
Number of subjects: 18
Study 8451310 — intervention group
Group type: EXPERIMENTAL
Intervention: 280 ml of CMW with 340 mg of encapsulated APM
Number of subjects: 18
Study 2870944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipothiazine palmitate (PPT) 100 mg alternating with placebo
Number of subjects: 39
Study 2870944 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol decanoate (FPX) 40 mg
Number of subjects: 39
Study 30833381 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D
Number of subjects: 1121
Study 30833381 — intervention group
Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 1121
Study 30833381 — intervention group
Group type: COMPARATOR
Intervention: Calcium plus Vitamin D
Number of subjects: 1121
Study 30833381 — intervention group
Group type: COMPARATOR
Intervention: Advanced or multiple adenomas
Number of subjects: 1121
Study 30440907 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPAEL Smart Board therapy (30 minutes a day, 5 days per week, for 4 weeks) in addition to traditional treatments (30 minutes of functional arm movement therapy)
Number of subjects: 17
Study 30440907 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (two 30-minute sessions, 5 days per week, for 4 weeks)
Number of subjects: 17
Study 26586610 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid LT4 at breakfast
Number of subjects: 77
Study 26586610 — intervention group
Group type: COMPARATOR
Intervention: Placebo before breakfast
Number of subjects: 77
Study 25132122 — intervention group
Group type: EXPERIMENTAL
Intervention: HCB+nopal
Number of subjects: 14
Study 25132122 — intervention group
Group type: EXPERIMENTAL
Intervention: HSPB+nopal
Number of subjects: 14
Study 22806823 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 22
Study 22806823 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 22
Study 22806823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg
Number of subjects: 22
Study 22806823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21265123 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex preventive therapy including wobenzym
Number of subjects: 0
Study 17309376 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 10
Study 17309376 — intervention group
Group type: COMPARATOR
Intervention: Breathing Retraining (BR)
Number of subjects: 10
Study 16298720 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV haplotype (intermediate PTC/PROP taste sensitivity)
Number of subjects: 567
Study 16298720 — intervention group
Group type: COMPARATOR
Intervention: PAV haplotype (taster)
Number of subjects: 567
Study 16298720 — intervention group
Group type: COMPARATOR
Intervention: AVI haplotype (nontaster)
Number of subjects: 567
Study 16298720 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste motivation measured by the Wisconsin Inventory of Smoking Dependence Motives‐68 taste/sensory processes scale
Number of subjects: 567
Study 12212981 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant
Number of subjects: 14
Study 12212981 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 14
Study 9469682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol (HDL) 5 mg plus lorazepam (LZ) 2 mg (9 patients)
Number of subjects: 20
Study 9469682 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular lorazepam (LZ) 2 mg (11 patients)
Number of subjects: 20
Study 7628515 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise with inflated cuffs around thighs
Number of subjects: 26
Study 7628515 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise without inflated cuffs
Number of subjects: 26
Study 7628515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise using arms
Number of subjects: 26
Study 7628515 — intervention group
Group type: COMPARATOR
Intervention: Cycle exercise using legs
Number of subjects: 26
Study 2744799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg daily)
Number of subjects: 35
Study 2744799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31271891 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromandibular transparotid approach (Group A)
Number of subjects: 26
Study 31271891 — intervention group
Group type: COMPARATOR
Intervention: Retromandibular anteroparotid approach (Group B)
Number of subjects: 26
Study 28758796 — intervention group
Group type: EXPERIMENTAL
Intervention: Film on idiopathic environmental intolerance (IEI)
Number of subjects: 212
Study 28758796 — intervention group
Group type: EXPERIMENTAL
Intervention: Film on the dangers of electromagnetic fields
Number of subjects: 212
Study 28758796 — intervention group
Group type: COMPARATOR
Intervention: Control film about cystic fibrosis
Number of subjects: 212
Study 28758796 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 212
Study 27117727 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-Pattern Training (MPT)
Number of subjects: 35
Study 27117727 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (Control)
Number of subjects: 35
Study 25616927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (BIV-LOW) at 0.25 mg/kg/h
Number of subjects: 2196
Study 25616927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (BIV-PCI) at 1.75 mg/kg/h
Number of subjects: 2196
Study 25616927 — intervention group
Group type: COMPARATOR
Intervention: Heparin ± GPI
Number of subjects: 2196
Study 25616927 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AST
Number of subjects: 2196
Study 25616927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2196
Study 25616927 — intervention group
Group type: EXPERIMENTAL
Intervention: BIV-LOW
Number of subjects: 2196
Study 23505929 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg oral dose administered 4 hours before the match)
Number of subjects: 12
Study 23505929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered to the control group)
Number of subjects: 12
Study 23505929 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Allopurinol and Placebo
Number of subjects: 12
Study 21382864 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen room sessions (30 minutes, twice a week for six weeks)
Number of subjects: 24
Study 21382864 — intervention group
Group type: COMPARATOR
Intervention: Volunteer visits (control group)
Number of subjects: 24
Study 19112801 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gel (topical gel containing growth factors, cytokines, and soluble matrix proteins)
Number of subjects: 60
Study 19112801 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 60
Study 16410447 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT‐FFP
Number of subjects: 121
Study 16410447 — intervention group
Group type: COMPARATOR
Intervention: C‐FFP
Number of subjects: 121
Study 14653030 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis using recombinant growth-factor protein application or growth factor gene therapy.
Number of subjects: 0
Study 14653030 — intervention group
Group type: COMPARATOR
Intervention: Angiogenic therapy (specifics not provided).
Number of subjects: 0
Study 11096046 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium (Gd-BOPTA dimeglumine), 0.2 mmol/kg
Number of subjects: 32
Study 11096046 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 32
Study 9248314 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated COOP charts
Number of subjects: 0
Study 9248314 — intervention group
Group type: COMPARATOR
Intervention: Unillustrated COOP charts
Number of subjects: 0
Study 8445223 — intervention group
Group type: EXPERIMENTAL
Intervention: Plugged-percutaneous biopsy
Number of subjects: 100
Study 8445223 — intervention group
Group type: COMPARATOR
Intervention: Transjugular biopsy
Number of subjects: 100
Study 3530634 — intervention group
Group type: EXPERIMENTAL
Intervention: Steel Ring
Number of subjects: 600
Study 3530634 — intervention group
Group type: EXPERIMENTAL
Intervention: VCu200
Number of subjects: 600
Study 3530634 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu220c
Number of subjects: 600
Study 28715800 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized Progesterone (MP)
Number of subjects: 120
Study 28715800 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo Medroxyprogesterone 17‐acetate (MPA)
Number of subjects: 120
Study 28715800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (DIE)
Number of subjects: 120
Study 28715800 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 27052661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive eating intervention
Number of subjects: 0
Study 22515360 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily, Amoxicillin 1 g twice daily, Levofloxacin 500 mg once daily for 7 days
Number of subjects: 128
Study 22515360 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg twice daily, Amoxicillin 1 g twice daily, Tetracycline 500 mg four times daily for 14 days
Number of subjects: 128
Study 20513227 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily extended-release methylphenidate (MPH)
Number of subjects: 49
Study 20513227 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily immediate-release methylphenidate (MPH)
Number of subjects: 49
Study 20513227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 20513227 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy during structured situations
Number of subjects: 49
Study 18541180 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter invitation to re-enroll
Number of subjects: 2400
Study 18541180 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter with ethnic-specific content invitation to re-enroll
Number of subjects: 2400
Study 18541180 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter and telephone call invitation to re-enroll
Number of subjects: 2400
Study 18541180 — intervention group
Group type: COMPARATOR
Intervention: No invitation to re-enroll
Number of subjects: 2400
Study 16410734 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with diuretic indapamide and angiotensin-converting enzyme inhibitor perindopril if required
Number of subjects: 600
Study 16410734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 12818954 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-loaded microcapsules
Number of subjects: 0
Study 12818954 — intervention group
Group type: COMPARATOR
Intervention: Aqueous bupivacaine
Number of subjects: 0
Study 10685583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground-level oxygen (GLO) treatment for 2 hours
Number of subjects: 801
Study 9332329 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B 1 mg/kg/d (c‐AMB)
Number of subjects: 338
Study 9332329 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B 1 mg/kg/d (L‐AMB1)
Number of subjects: 338
Study 9332329 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B 3 mg/kg/d (L‐AMB3)
Number of subjects: 338
Study 8229130 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued testicular androgen suppression
Number of subjects: 341
Study 8229130 — intervention group
Group type: COMPARATOR
Intervention: Discontinued exogenous endocrine therapy
Number of subjects: 341
Study 3094063 — intervention group
Group type: EXPERIMENTAL
Intervention: Desamino-D-arg8-vasopressin (DDAVP) 20 or 60 micrograms/subject
Number of subjects: 0
Study 3094063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (EtOH) 0.33 ml/kg
Number of subjects: 0
Study 3094063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (EtOH) 1.0 ml/kg
Number of subjects: 0
Study 30903329 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 ml PEG + Asc (Regimen A)
Number of subjects: 60
Study 30903329 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ml PEG + Asc (Regimen B)
Number of subjects: 60
Study 30903329 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml PEG + Asc (Regimen C)
Number of subjects: 60
Study 30903329 — intervention group
Group type: COMPARATOR
Intervention: Regimen A vs Regimen B
Number of subjects: 60